MCRB — Seres Therapeutics Share News
0.000.00%
Last trade - 00:00- $20.78m
- $5.18m
- $0.79m
Brief: Seres Therapeutics - May Offer Up To $300 Million Of Securities
Seres Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Seres Therapeutics Q2 net income turns positive on VOWST sale gain
Brief: Seres Therapeutics Q2 EPS USD 0.47
Seres Therapeutics Inc expected to post a loss of $2.18 a share - Earnings Preview
Brief: Seres Therapeutics Announces Two Transactions To Strengthen Balance Sheet, Reduce On-Going Lease Costs And Extend Projected Operating Cash Runway Well Into The First Quarter Of 2027
Seres Therapeutics reports Q1 net loss
CATL launches lighter battery to meet higher efficiency requirement (updated)
China's CATL beats first quarter forecasts, boosting market dominance (updated)
China's CATL posts slower profit growth in first quarter
Seres Therapeutics posts 2025 profit as expenses fall
Brief: Seres Therapeutics FY EPS USD 0.64
NASDAQ RESUMED AT 07:30 AM
Brief: Seres Provides Program And Corporate Updates And Prioritizes Emerging Programs In Inflammatory & Immune Diseases
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Huawei-backed Aito teams up with UAE dealer to kick off exports (updated)
Seres Therapeutics Q3 net income $8.2 mln, reverses loss
Brief: Seres Therapeutics Q3 EPS USD 0.94
Advisory: Dated alerts on Seres Therapeutics' measures to cut costs withdrawn